| Literature DB >> 25659267 |
Jolanda Brummelman1, Kina Helm2, Hendrik-Jan Hamstra2, Peter van der Ley3, Claire J P Boog3, Wanda G H Han2, Cécile A C M van Els2.
Abstract
Whole cell pertussis (wP) vaccines are gradually being replaced by aluminum salt-adjuvanted acellular pertussis (aP) vaccines. These promote CD4(+) T cell responses with a non-protective Th2 component, while protective immune mechanisms to B. pertussis may rather involve long-lived Th1/Th17 type CD4(+) T cells. Here we asked whether addition of a non-toxic meningococcal LPS derivative, LpxL1, as adjuvant can favorably modulate the aP-induced pertussis-specific CD4(+) T cell response in mice. To assess the effect of TLR4 ligation, Th type, quantity, and memory potential of pertussis-specific CD4(+) T cells were determined at the single-cell level after aP and aP+LpxL1 vaccination using intracellular cytokine staining and MHC class II tetramers. Adding LpxL1 to the aP vaccine weakened the Th2 component and strengthened the Th1/Th17 component of the specific CD4(+) T cell response. Notably, LpxL1 addition also induced higher frequencies of tetramer positive CD4(+) T cells in draining lymph nodes or blood, depending on the phase after vaccination. Moreover, there was a net profit in the number of CD4(+) T cells with a central memory phenotype, preferred for long-term immunity. Thus, adding a TLR4 ligand as adjuvant to a current aP vaccine was associated with a more favorable pertussis-specific CD4(+) T cell response.Entities:
Keywords: Acellular pertussis vaccine; Adjuvants; Bordetella pertussis; CD4 T cells; Memory T cells; TLR4
Mesh:
Substances:
Year: 2015 PMID: 25659267 DOI: 10.1016/j.vaccine.2015.01.063
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641